Business Wire

Virtuozzo Acquires OnApp, Enabling More Comprehensive Intuitive Cloud Infrastructure Solutions for Service Providers

20.7.2021 11:00:00 EEST | Business Wire | Press release

Share

Virtuozzo’s mission is to help shape the future of the cloud by empowering service providers with comprehensive, high performance, flexible and easy-to-use cloud infrastructure solutions supporting private, public and hybrid cloud use cases. To that end, Virtuozzo, a global leader in high-efficiency virtualization and hyperconverged software solutions, today announced it is acquiring OnApp, a London-based software company focused on cloud solutions for service providers. The acquisition augments Virtuozzo’s existing cloud IaaS and PaaS products while expanding its regional market reach.

Future-proofed Cloud Flexibility, Simplicity and Automation

The combined technological and R&D strengths of both companies directly target the evolving needs of Cloud Service Providers (CSPs), Managed Service Providers (MSPs), and Hosting Providers focused on providing IaaS, PaaS and XaaS solutions for their customers.

The resulting solution stack will pair Virtuozzo’s easy-to-use virtualization, containerization, storage and orchestration capabilities with advanced features of OnApp’s flexible self-service management platform. In turn, service providers will gain access to today’s most intuitive and robust cloud infrastructure and platform solutions capable of supporting any cloud use case.

“Virtuozzo’s primary expertise has traditionally been in high-density server virtualization and software-defined storage. We have successfully expanded over the last few years into hyperconverged infrastructure as it is crucial to the market’s evolution,” said Alex Fine, Virtuozzo CEO. “Simple, flexible and smart access to those strong, fundamental technologies is core to the success of MSPs, CSPs and Hosting Providers and therefore, core to ours. OnApp shares that commitment and brings to Virtuozzo incredible engineering talent and complementary technologies that help us advance the cloud infrastructure industry as a whole. We’re proud and excited to have the OnApp team on board.”

Market Growth Driving Innovation

Timing and demand are key factors behind the acquisition. Synergy Research Group recently reported that cloud infrastructure demand reached $129 billion in 2020, growing 35% year over year. About a third of this market is owned by non-hyperscalers—local, regional and multi-national service providers. Those providers are the beneficiaries of Virtuozzo technology.

In parallel, 451 Research, a part of S&P Global Market Intelligence, recently discussed in its 2021 analysis Demand and Opportunity in the Alternative Cloud Provider Market a potential new opportunity for alternative CSPs, noting that they may find a role in larger multi-cloud portfolios and that “alternative can mean ‘in addition to’ rather than ‘instead of.’”1 Collectively, these reports suggest that alternative CSPs and MSPs are well-positioned to become partners of choice for customers shifting to modern cloud services.

“In addition to OnApp technical expertise in cloud orchestration, user interface and content delivery networks, Virtuozzo sees the value our highly talented staff brings to the table,” stated Ditlev Bredahl, CEO, OnApp. “Integration and evolution of the joint solution stack will be strongly beneficial to the customers of both companies.”

Terms of the transaction were not disclosed. Per the agreement, OnApp will continue operation as a division of Virtuozzo with OnApp’s staff integrating into Virtuozzo’s organizational structure. Business will continue as usual with Bredahl assisting with post-acquisition integration.

About OnApp

OnApp provides software and services that enable hosts, MSPs and telecoms providers to create and sell their own public, private and hybrid clouds. OnApp launched in July 2010, and to date has deployed more than 6,000 clouds for service providers in 93 countries. OnApp has 130 staff across the EU, U.S. and Asia-Pacific and is headquartered in London, UK. For more information, visit https://onapp.com.

About Virtuozzo

Virtuozzo (www.virtuozzo.com) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 450 service providers, ISVs, and enterprises worldwide to enable over 500 thousand virtual environments, running mission-critical cloud workloads. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.

1 Demand and Opportunity in the Alternative Cloud Provider Market, Liam Eagle, 451 Research, a part of S&P Global Market Intelligence. January 2021.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Heather Ailara/Deb Brown
211 Communications
+1.973.567.6040
heather@211comms.com / deb@211comms.com

Christine Brunelli
Virtuozzo
+1 215-847-7842
christine.brunelli@virtuozzo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye